Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

AMLX 11.27.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:7th Annual Evercore ISI HealthCONx Conference
Full Press ReleaseSEC FilingsOur AMLX Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
  • 01.10.2025 - Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  • 01.10.2025 - Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Recent Filings

  • 01.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
  • 01.10.2025 - 8-K Current report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 27, 2024--Amylyx Pharmaceuticals, Inc.(Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the 7th AnnualEvercore ISI HealthCONx Conference. The conference is being conducted in-person inCoral Gables, Florida, and the fireside chat will take place onWednesday, December 4, 2024, at11:15 a.m. ET.

A live webcast of the fireside chat can be accessed under “Events and Presentations” in the Investor section of the Company’s website,https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the event.

AboutAmylyx Pharmaceuticals

Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions. Since its founding, Amylyx has been guided by science to address unanswered questions, keeping communities at the heart and center of all decisions. Amylyx is headquartered inCambridge, Massachusetts. For more information, visitamylyx.comand follow us onLinkedInandX. For investors, please visitinvestors.amylyx.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241127937550/en/

MediaAmylyx Media Team+1 (857) 799-7274amylyxmediateam@amylyx.com

InvestorsLindsey AllenAmylyx Pharmaceuticals, Inc.+1 (857) 320-6244Investors@amylyx.com

Source:Amylyx Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com